Seladelpar could eventually become the standard second-line treatment for primary biliary cholangitis, according to phase 3 findings presented at the 2020 Liver Meeting of the American Association for the Study of Liver Diseases.
Seladelpar (CymaBay) is the only selective PPAR-delta agonist in development for the treatment of PBC, which occurs more often in women than men. The current second-line therapy for PBC is obeticholic acid (Ocaliva, Intercept Pharmaceuticals).
For much of 2020, CymaBay